Suzanne M de la Monte, Erin Elgas, Ming Tong, Busra Delikkaya, Yiwen Yang
Background: Central Nervous System (CNS) abnormalities with insulin resistance and mediated by developmental exposures to ethanol can be avoided or remediated by consumption of dietary soy, which has insulin-sensitizing as well as antioxidant effects. However, choline supplementation has been shown to diminish Fetal Alcohol Spectrum Disorder (FASD) pathologies, and dietary soy contains abundant choline. This study was designed to determine if the therapeutic effects of soy were mediated by or independent of choline.
Methods: Human PNET2 cells exposed to 0 mM or 100 mM ethanol for 48 hours were seeded into 96-well or 12-well plates and treated with vehicle, choline chloride (75 μM), or 1 μM Daidzein+1 μM Genistein (D+G) for 24 h. The cells were then analyzed for viability (Hoechst 33342), mitochondrial function (MTT), and GAPDH, Tau, Acetyl Cholinesterase (AChE), Choline Acetyl Transferase (ChAT), and Aspartyl-Asparaginyl-β-Hydroxylase (ASPH) immunoreactivity.
Results: Choline and D+G significantly increased MTT activity (mitochondrial function) corrected for cell number relative to vehicle in control and ethanol-exposed cultures. Both choline and D+G prevented the ethanol-induced inhibition of GAPDH and ChAT and increased cellular accumulations of Tau. However, D+G significantly increased ASPH expression relative to vehicle and Choline.
Conclusion: Choline and D+G differentially modulated the expression of neuronal proteins, mitochondrial function, and ASPH. Importantly, the prominently increased expression of ASPH by D+G corresponds with the insulin-sensitizer actions of soy isoflavones since ASPH is an insulin-responsive molecule. The findings further suggest that dietary soy may be more effective than choline for reducing ethanol-impaired neuronal migration linked to ASPH inhibition in FASD.
{"title":"Differential rescue effects of choline chloride and soy isolate on metabolic dysfunction in immature central nervous system neurons: Relevance to fetal alcohol spectrum disorder.","authors":"Suzanne M de la Monte, Erin Elgas, Ming Tong, Busra Delikkaya, Yiwen Yang","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Central Nervous System (CNS) abnormalities with insulin resistance and mediated by developmental exposures to ethanol can be avoided or remediated by consumption of dietary soy, which has insulin-sensitizing as well as antioxidant effects. However, choline supplementation has been shown to diminish Fetal Alcohol Spectrum Disorder (FASD) pathologies, and dietary soy contains abundant choline. This study was designed to determine if the therapeutic effects of soy were mediated by or independent of choline.</p><p><strong>Methods: </strong>Human PNET2 cells exposed to 0 mM or 100 mM ethanol for 48 hours were seeded into 96-well or 12-well plates and treated with vehicle, choline chloride (75 μM), or 1 μM Daidzein+1 μM Genistein (D+G) for 24 h. The cells were then analyzed for viability (Hoechst 33342), mitochondrial function (MTT), and GAPDH, Tau, Acetyl Cholinesterase (AChE), Choline Acetyl Transferase (ChAT), and Aspartyl-Asparaginyl-β-Hydroxylase (ASPH) immunoreactivity.</p><p><strong>Results: </strong>Choline and D+G significantly increased MTT activity (mitochondrial function) corrected for cell number relative to vehicle in control and ethanol-exposed cultures. Both choline and D+G prevented the ethanol-induced inhibition of GAPDH and ChAT and increased cellular accumulations of Tau. However, D+G significantly increased ASPH expression relative to vehicle and Choline.</p><p><strong>Conclusion: </strong>Choline and D+G differentially modulated the expression of neuronal proteins, mitochondrial function, and ASPH. Importantly, the prominently increased expression of ASPH by D+G corresponds with the insulin-sensitizer actions of soy isoflavones since ASPH is an insulin-responsive molecule. The findings further suggest that dietary soy may be more effective than choline for reducing ethanol-impaired neuronal migration linked to ASPH inhibition in FASD.</p>","PeriodicalId":89355,"journal":{"name":"Diabetes management (London, England)","volume":"13 Suppl 1","pages":"107-118"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11595351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142735068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37532/1758-1907.2021.11(7).254-255
Ramya Velluri
Type 2 diabetes is represented by elevated glucose levels brought about by insulin resistance. Insulin is a chemical that assists glucose with entering cells, it can be utilized for energy or put away for some time later. Insulin resistance happens when cells in the body don’t react well to insulin and consequently don’t eliminate glucose from the blood. In type 2 diabetes, insulin resistance likewise builds the body’s creation of insulin, which can prompt expanded craving, hypertension, and weight acquire.
{"title":"Hepatic drugs (GABA) is essential for type 2 diabetes treatment","authors":"Ramya Velluri","doi":"10.37532/1758-1907.2021.11(7).254-255","DOIUrl":"https://doi.org/10.37532/1758-1907.2021.11(7).254-255","url":null,"abstract":"Type 2 diabetes is represented by elevated glucose levels brought about by insulin resistance. Insulin is a chemical that assists glucose with entering cells, it can be utilized for energy or put away for some time later. Insulin resistance happens when cells in the body don’t react well to insulin and consequently don’t eliminate glucose from the blood. In type 2 diabetes, insulin resistance likewise builds the body’s creation of insulin, which can prompt expanded craving, hypertension, and weight acquire.","PeriodicalId":89355,"journal":{"name":"Diabetes management (London, England)","volume":"11 1","pages":"254-255"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69923497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37532/1758-1907.2021.11(5).227
Javier
{"title":"4th Annual Congress on Diabetes, Obesity and Its Complications during September 28-29, 2020 in Singapore","authors":"Javier","doi":"10.37532/1758-1907.2021.11(5).227","DOIUrl":"https://doi.org/10.37532/1758-1907.2021.11(5).227","url":null,"abstract":"","PeriodicalId":89355,"journal":{"name":"Diabetes management (London, England)","volume":"11 1","pages":"227"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69923795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37532/1758-1907.2021.11(7).257-264
Anja Schuster, C. Roth, L. Stechemesser, R. Weitgasser, Karin Schwenoha Gertie Janneke Oostingh
Objective: Accurate and reliable blood glucose monitoring devices (BGMDs) are required for adequate self-monitoring and management for people suffering from diabetes mellitus. To ensure a high level of safety for patients and users of in vitro diagnostic devices, an updated In Vitro Diagnostic Regulation (IVDR 2017/746) has been published, including new safety and performance prerequisites. However, BGMD accuracy may be limited by certain ‘real-life’ environmental factors, which should be respected in the performance evaluation. Methods: The temperature-and humidity-dependent performance of 4 different BGMD using up to 440 capillary blood samples was determined. BGMDs with associated test strips were stored at 15°C, 25°C and 35°C resp. at a relative humidity of 40% and 80% in order to imitate potential ‘real-life’ performance settings. Glucose measurements were compared to blood glucose values determined using standardized Laboratory equipment and were analyzed based on the ISO 15197:2013 system accuracy criteria. Results: Two out of three BGMDs provided consistent results across temperature ranges based on the medical threshold of a mean glucose change less than 15 mg/dl, although blood glucose difference of up to 96 mg/dl was found at an individual patient level after pairwise temperature comparison. For one device up to 31.2% of patients’ values were outside the defined limits when comparing 15o C to 35o C. Changes in humidity levels did not significantly influence the mean values across the BGMDs, although high deviations were observed at patients’ individual glucose levels. Conclusion: Moderate temperature and humidity changes can affect the accuracy of point-ofcare devices to a profound extent at an individual patient level. These ‘real-life’ environmental factors need to be included in the performance evaluation as required in the IVDR 2017/746 in order to provide a solid testing system for novel point-of-care-devices.
{"title":"Challenges for the implementation of the in-vitro diagnostics regulations in the light of â??real-lifeâ?? performance of blood glucose self-monitoring devices","authors":"Anja Schuster, C. Roth, L. Stechemesser, R. Weitgasser, Karin Schwenoha Gertie Janneke Oostingh","doi":"10.37532/1758-1907.2021.11(7).257-264","DOIUrl":"https://doi.org/10.37532/1758-1907.2021.11(7).257-264","url":null,"abstract":"Objective: Accurate and reliable blood glucose monitoring devices (BGMDs) are required for adequate self-monitoring and management for people suffering from diabetes mellitus. To ensure a high level of safety for patients and users of in vitro diagnostic devices, an updated In Vitro Diagnostic Regulation (IVDR 2017/746) has been published, including new safety and performance prerequisites. However, BGMD accuracy may be limited by certain ‘real-life’ environmental factors, which should be respected in the performance evaluation. Methods: The temperature-and humidity-dependent performance of 4 different BGMD using up to 440 capillary blood samples was determined. BGMDs with associated test strips were stored at 15°C, 25°C and 35°C resp. at a relative humidity of 40% and 80% in order to imitate potential ‘real-life’ performance settings. Glucose measurements were compared to blood glucose values determined using standardized Laboratory equipment and were analyzed based on the ISO 15197:2013 system accuracy criteria. Results: Two out of three BGMDs provided consistent results across temperature ranges based on the medical threshold of a mean glucose change less than 15 mg/dl, although blood glucose difference of up to 96 mg/dl was found at an individual patient level after pairwise temperature comparison. For one device up to 31.2% of patients’ values were outside the defined limits when comparing 15o C to 35o C. Changes in humidity levels did not significantly influence the mean values across the BGMDs, although high deviations were observed at patients’ individual glucose levels. Conclusion: Moderate temperature and humidity changes can affect the accuracy of point-of\u0002care devices to a profound extent at an individual patient level. These ‘real-life’ environmental factors need to be included in the performance evaluation as required in the IVDR 2017/746 in order to provide a solid testing system for novel point-of-care-devices.","PeriodicalId":89355,"journal":{"name":"Diabetes management (London, England)","volume":"11 1","pages":"257-264"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69923570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37532/1758-1907.2021.11(5).228
A. Khomassuridze
The award should motivate individuals to strive to realize their fullest potential which could, in turn, be beneficial to the field as a whole. Epic works are not only a testament to the individual’s efforts, but they also have the potential to change the whole world as they can lead to the formulation of better policies and or a new mindset.
{"title":"Global Meet on Obesity and Diabetes","authors":"A. Khomassuridze","doi":"10.37532/1758-1907.2021.11(5).228","DOIUrl":"https://doi.org/10.37532/1758-1907.2021.11(5).228","url":null,"abstract":"The award should motivate individuals to strive to realize their fullest potential which could, in turn, be beneficial to the field as a whole. Epic works are not only a testament to the individual’s efforts, but they also have the potential to change the whole world as they can lead to the formulation of better policies and or a new mindset.","PeriodicalId":89355,"journal":{"name":"Diabetes management (London, England)","volume":"119 1","pages":"228"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69923851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37532/1758-1907.2021.11(6).231-241
G. Penna, A. Girelli, F. Bertuzzi, R.Celleno, M. Scavini, P. Tripodi, M.Zanon, R. Bartolo
Young age onset and long-life expectancy of type 1 diabetes mellitus (T1DM) people make it essential to achieve an early, stable and optimal glycemic control to prevent chronic complications and ensure good quality of life. These goals can only be achieved by having a healthcare organization that guarantees patient equity of access, quality and continuity of care, with an appropriate use of resources. To make the treatment organization efficient and appropriate, various health systems have implemented Diagnostic Therapeutic Assistance Paths (DTAP). DTAPs aim to share decision-making processes and healthcare organization for specific groups of patients on the basis of existing guidelines and in relation to the available resources, during a well-defined period of time. In Italy, the Italian Association of Diabetologists (AMD) scientific society, in association with Association of Pediatric Endocrinologists and Diabetologists (SIEDP), and voluntary diabetes associations (i.e. Diabetes Italia) developed a national DTAP for T1DM. Five DTAP models were defined, focusing on 5 different disease stages or treatment process: onset of illness or first referral from another diabetes clinic, routine visit in good metabolic control, uncontrolled hyperglycemia, advanced technologies, transition from pediatric to adult diabetes clinic. Objectives, healthcare professionals involved, visits organization, and educational contents for each of these PDTAs are detailed in the core document. This DTAP will be disseminated through the AMD regional referents to the Regional Healthcare Systems. Each Region will be asked to implement the DTAP through multi-professional working groups, with the participation of regional AMD referents and representatives of Patient Associations. The DTAP effectiveness will be evaluated using an indicators’ system every year.
{"title":"Diagnostic - Therapeutic - Assistance Paths (DTAP) for type 1 diabetes mellitus: summary of the document of the Italian Ã?¢??Associazione Medici Diabetologi(AMD)Ã?¢?? scientific society","authors":"G. Penna, A. Girelli, F. Bertuzzi, R.Celleno, M. Scavini, P. Tripodi, M.Zanon, R. Bartolo","doi":"10.37532/1758-1907.2021.11(6).231-241","DOIUrl":"https://doi.org/10.37532/1758-1907.2021.11(6).231-241","url":null,"abstract":"Young age onset and long-life expectancy of type 1 diabetes mellitus (T1DM) people make it essential to achieve an early, stable and optimal glycemic control to prevent chronic complications and ensure good quality of life. These goals can only be achieved by having a healthcare organization that guarantees patient equity of access, quality and continuity of care, with an appropriate use of resources. To make the treatment organization efficient and appropriate, various health systems have implemented Diagnostic Therapeutic Assistance Paths (DTAP). DTAPs aim to share decision-making processes and healthcare organization for specific groups of patients on the basis of existing guidelines and in relation to the available resources, during a well-defined period of time. In Italy, the Italian Association of Diabetologists (AMD) scientific society, in association with Association of Pediatric Endocrinologists and Diabetologists (SIEDP), and voluntary diabetes associations (i.e. Diabetes Italia) developed a national DTAP for T1DM. Five DTAP models were defined, focusing on 5 different disease stages or treatment process: onset of illness or first referral from another diabetes clinic, routine visit in good metabolic control, uncontrolled hyperglycemia, advanced technologies, transition from pediatric to adult diabetes clinic. Objectives, healthcare professionals involved, visits organization, and educational contents for each of these PDTAs are detailed in the core document. This DTAP will be disseminated through the AMD regional referents to the Regional Healthcare Systems. Each Region will be asked to implement the DTAP through multi-professional working groups, with the participation of regional AMD referents and representatives of Patient Associations. The DTAP effectiveness will be evaluated using an indicators’ system every year.","PeriodicalId":89355,"journal":{"name":"Diabetes management (London, England)","volume":"11 1","pages":"231-241"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69923511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37532/1758-1907.2021.11(7).265-269
Sangoyomi Seun A Akinola Oluwole
Diabetes mellitus is the most common metabolic disease with neuropathy as its most common complication. In the present study, the effects of oral hypoglycaemic drugs (metformin, pioglitazone and rosiglitazone) on the morphology of the sciatic nerve were investigated. Forty male Wistar rats (140 g) divided into 5 groups control, diabetic, and 3 experimental groups (n=8) were used for the study. The 3 experimental groups were rendered diabetic by intraperitoneal injection of alloxan (150 mg/kg body weight) and subsequently treated with metformin (150 mg/kg/d), pioglitazone (3 mg/kg/d) and rosiglitazone (10 mg/kg/d) respectively. At 28 days of treatment, sciatic nerve morphology was studied by the Bielschosky’s Silver Nitrate (BSN) and Luxol Fast Blue (LFB) techniques. Blood glucose levels were monitored and recorded throughout the experiment. In the diabetic rats with oral hypoglycaemic interventions, blood glucose was not significantly different (P>0.05) from the control at 28 days of treatment. The body weight of Rosiglitazone-treated rats showed significant increase when compared with the control and other oral hypoglycaemic drug-treated rats. The axon and myelin fibers showed relatively strong affinity for BSN and LFB in the control and oral hypoglycaemic drugtreated diabetic rats contrary to the weak affinity for the stains in the untreated diabetic rats. These results suggest that oral hypoglycaemic drugs exerted positive effects on the treatment and improvement of sciatic nerve morphology of alloxan-induced diabetic rats.
{"title":"The comparative effects of metformin, pioglitazone and rosiglitazone on the sciatic nerve of alloxan-induced diabetic male rats","authors":"Sangoyomi Seun A Akinola Oluwole","doi":"10.37532/1758-1907.2021.11(7).265-269","DOIUrl":"https://doi.org/10.37532/1758-1907.2021.11(7).265-269","url":null,"abstract":"Diabetes mellitus is the most common metabolic disease with neuropathy as its most common complication. In the present study, the effects of oral hypoglycaemic drugs (metformin, pioglitazone and rosiglitazone) on the morphology of the sciatic nerve were investigated. Forty male Wistar rats (140 g) divided into 5 groups control, diabetic, and 3 experimental groups (n=8) were used for the study. The 3 experimental groups were rendered diabetic by intraperitoneal injection of alloxan (150 mg/kg body weight) and subsequently treated with metformin (150 mg/kg/d), pioglitazone (3 mg/kg/d) and rosiglitazone (10 mg/kg/d) respectively. At 28 days of treatment, sciatic nerve morphology was studied by the Bielschosky’s Silver Nitrate (BSN) and Luxol Fast Blue (LFB) techniques. Blood glucose levels were monitored and recorded throughout the experiment. In the diabetic rats with oral hypoglycaemic interventions, blood glucose was not significantly different (P>0.05) from the control at 28 days of treatment. The body weight of Rosiglitazone-treated rats showed significant increase when compared with the control and other oral hypoglycaemic drug-treated rats. The axon and myelin fibers showed relatively strong affinity for BSN and LFB in the control and oral hypoglycaemic drug\u0002treated diabetic rats contrary to the weak affinity for the stains in the untreated diabetic rats. These results suggest that oral hypoglycaemic drugs exerted positive effects on the treatment and improvement of sciatic nerve morphology of alloxan-induced diabetic rats.","PeriodicalId":89355,"journal":{"name":"Diabetes management (London, England)","volume":"11 1","pages":"265-269"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69923632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号